Drug Approval | December 28, 2021
Dr Reddy’s receives Emergency Use Authorisation for molnupiravir
The company will market it under the brand name Molflu
The company will market it under the brand name Molflu
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Dr. Reddy's valsartan tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90
Sputnik M is a new member of the Sputnik vaccines family
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Subscribe To Our Newsletter & Stay Updated
